Sandoz Splits Out Biosimilars And Generics With New Business Structure

Armin Metzger Joins To Lead Biosimilars Amid Management Reshuffle

 
• By Dave Wallace
  
Sandoz is separating out its generics and biosimilars businesses (Shutterstock)

More from Strategy

More from Business